Salicylanilides: Selective inhibitors of interleukin-12p40 production

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 18, 2008, Pages 8760-8764

  Brown, Michael E ^a   Fitzner, Jeffrey N ^a   Stevens, Tracey ^a   Chin, Wilson ^a   Wright, Clifford D ^a   Boyce, Jim P ^a  

^a AMGEN INC   (United States)

Author keywords

Interleukin 12 (IL 12); Interleukin 12p40 (IL 12p40); Interleukin 23 (IL 23); Interleukin 6 (IL 6); Salicylanilide

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 6; SALICYLANILIDE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG POTENCY; FLUORESCENCE; GENE EXPRESSION PROFILING; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL ASSAY; CELL MEMBRANE; CELLS, CULTURED; DENDRITIC CELLS; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23; INTERLEUKIN-6; MICE; SALICYLANILIDES; SIGNAL TRANSDUCTION;

EID: 51449089064     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.07.024     Document Type: Article

References (21)

1. Trinchieri G., Pflanz S., and Kastelein R.A. Immunity 19 (2003) 641-644
2. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., and Presky D.H. Annu. Rev. Immunol. 16 (1998) 495-521
3. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., Dolin B., Goodman N., Groden C., Hornung R.L., Quezado M., Neurath M.F., Salfeld J., Veldman G.M., Schwertschlag U., and Strober W. New Engl. J. Med. 351 (2004) 2069-2079
4. Toichi E., Torres G., McCormick T.S., Chang T., Mascelli M.A., Kauffman C.L., Aria N., Gottlieb A.B., Everitt D.E., Frederick B., Pendley C.E., and Cooper K.D. J. Immunol. 177 7 (2006) 4917-4926
5. Burakoff R., Barish C.F., Riff D., Pruitt R., Chey W.Y., Farraye F.A., Shafran I., Katz S., Krone C.L., Vander V.M., Stevens C., Sherman M.L., Jacobson E., and Bleday R. Inflamm. Bowel Dis. 12 7 (2006) 558-565
6. Coopera A.M., and Khader S.A. Trends Immunol. 28 1 (2007) 33-38
7. For leading references on anti-bacterial activities of salicylanilides see the following and Ref. 8. Waisser K., Matyk J., Divišová H., Husáková P., Kuneš J., Klimešová V., Kaustová J., Möllmann U., Dahse H.-M., and Miko M. Arch. Pharm. 339 11 (2006) 616-620
8. Fuente R.D.L., Sonawane N.D., Arumainayagam D., and Verkman A.S. Br. J. Pharmacol. 149 (2006) 551-559
9. Kasckow J.W., Tabira T., Itoyama Y., Kuroiwa Y., Takenaka A., and Nagai Y. Jpn. J. Exp. Med. 515 (1981) 293-298
10. Zhu X.-F., Wang J.-S., Cai L.-L., Zeng Y.-X., and Yang D. Cancer Sci. 971 (2006) 84-89
11. Agrawal V.K., and Sharma S. Pharmazie 396 (1984) 373-378
12. Compounds 1 and 2 were not included among the original compounds that we evaluated for inhibition of IL-12p40 production.
13. Inhibition of IL-12p40 production was also assessed using primary human dendritic cells however the human donor-to-donor cell variability of these primary cells and the difficulty posed by their routine collection made their use difficult thus a murine dentritic cell line was used for routine SAR development.
14. A similar observation can be made by comparing compounds 13 and 8. One hypothesis for this effect would invoke subtle differences in interactions with different target proteins.
15. TM 9.0, Advanced Chemistry Development, Inc., (ACD/Labs), Toronto, ON, Canada, www.acdlabs.com.
16. Biochemical target identification, in order to understand the mechanism of action of these salicylanilides, will be reported elsewhere.
17. Thomas, M. G.; Allanson, N. M. Brit. UK Pat. Appl. 2002, 13 pp.
18. Liechti C., Sequin U., Bold G., Furet P., Meyer T., and Traxler P. Eur. J. Med. Chem. 391 (2004) 11-26
19. Muto S., Nagano T., Saotome T., and Itai A. PCT Int. Appl. (2002) 313
20. Eriksson U., Kurrer M.O., Sonderegger I., Iezzi G., Tafuri A., Hunziker L., Suzuki S., Bachmaier K., Bingisser R.M., Penninger J.M., and Kopf M. J. Exp. Med. 197 3 (2003) 323-331
21. Pasare C., and Medzhitov R. Science 299 5609 (2003) 1033-1036